Fast Five Quiz: Aromatic L-Amino Acid Decarboxylase Deficiency Diagnosis and Management

Stephen L. Nelson, Jr, MD, PhD


September 18, 2020

Dopamine agonists, preferably non–ergot-derived, should be considered to treat patients with AADC deficiency. Dopamine agonists directly activate postsynaptic dopamine receptors. Because ergot-derived agonists with strong serotonergic (5-HT2b) agonist action are strongly associated with cardiac valvulopathy and other fibrotic complications, these types of dopamine agonists should not be used to treat patients with AADC deficiency. Non–ergot-derived dopamine agonists, on the other hand, probably have very low risk of fibrous complications.

Although ergot-derived dopamine agonists without 5-HT2b agonist action have a lower risk than those with 5-HT2b agonist action, cardiac screening should be carried out before and during treatment to monitor for cardiac fibrosis.

Learn more about AADC deficiency treatment.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: